Patients with Obstructive Sleep Apnea at Altitude

Area of Science:

• Altitude Medicine
• Sleep Medicine
• Cardiovascular Physiology

Background:

• Obstructive sleep apnea (OSA) is common, especially in older adults.
• At sea level, OSA involves upper airway collapse and intermittent hypoxemia.
• High altitude exacerbates OSA by causing central apneas and sustained hypoxia.

Purpose of the Study:

• To investigate the effects of high altitude on OSA patients.
• To assess cardiovascular and sympathetic responses to altitude in OSA.
• To recommend management strategies for OSA patients at altitude.

Main Methods:

• Review of randomized trials on OSA patients at high altitude.
• Analysis of physiological responses including heart rate, arrhythmia, and blood pressure.
• Evaluation of treatment efficacy for auto-CPAP and acetazolamide.

Main Results:

• High altitude (above 1600m) induces central apneas alongside obstructive events in OSA patients.
• This leads to combined intermittent and sustained hypoxia, triggering sympathetic activation.
• Elevated heart rate, cardiac arrhythmia, and hypertension are observed.
• Auto-CPAP with acetazolamide is recommended; acetazolamide alone offers partial benefit.

Conclusions:

• OSA patients face significant cardiovascular risks at high altitudes due to complex hypoxia.
• Continuous positive airway pressure (CPAP) with auto-adjustment and acetazolamide is advisable.
• Acetazolamide monotherapy is a viable alternative when CPAP is not feasible, improving oxygenation and mitigating hypertension.